[Analysis of relation between types of bony metastasis and PSA and tumor differentiation of prostate cancer]

Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):956-8.
[Article in Chinese]

Abstract

Objective: To analyze the relationship between radiological characteristics of bony metastasis and PSA, Gleason score (GS) for prostate cancer patients.

Methods: The investigators collected the clinical data of 44 patients with prostate cancer bony metastasis and divided them into 3 groups based upon the radiological characteristics of bony metastasis. The 3 groups were osteoblast group, osteoclast group and mixed group.

Results: The mean age of patients was 70 years old. There were 33 cases (75.00%), 9 cases (20.45%) and 2 cases (4.55%) in osteoblast group, osteoclast group and mixed group respectively. The mean total serum PSA values were 590.3+/-177.0 microg/L, 249.0+/-66.6 microg/L and 156.5+/-42.1 microg/L in osteoblast group, osteoclast group and mixed group respectively. No statistic significance was found for the difference of total PSA in 3 groups. Mean GS in osteoblast group was 7.4 (6-10). Twenty-two cases (66.7%) were of a medium-high differentiation (GS<or=7) while 11 cases (33.3%) of a low differentiation (GS>7). Mean GS in osteoclast group was 8.0 (6-10). Among which, 3 cases (33.3%) were of a medium-high differentiation while 6 cases (66.7%) of a low differentiation. Statistic significance was found for the difference of GS in 2 groups. Two cases in mixed group were assigned 8 of GS.

Conclusion: There is no confirmed correlation between types of bony metastasis and total serum PSA for prostate cancer patients. But the tumor differentiation reflected by Gleason score may affect the type of bony metastasis.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / secondary*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / pathology*

Substances

  • Prostate-Specific Antigen